- AEON and Daewoong Pharmaceutical have executed definitive documentation to exchange $15 million of notes plus accrued interest into new equity, $1.5 million of new notes due 2030, and a cash-exercise warrant for 8 million shares of common stock – - Exchange remains subject to shareholder approval - IRVINE, Calif., Dec. 15, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company seeking accelerated and full-label U.S. market entry by devel ...

EMERYVILLE, Calif., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX) (“Kyverna”), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today announced that it has commenced an underwritten public offering of $100,000,000 of shares of its common stock. Kyverna intends to grant the underwriters a 30-day option to purchase up to an additional $15,000,000 of shares of common stock offered in the public offering, at the ...

Conference call and webcast to be held at 8 a.m. ET on December 16, 2025BOSTON, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that management will host a live conference call and webcast on Tuesday, December 16, 2025, at 8:00 a.m. ET. The webcast presentation will highlight interim clinical results from the ongoing Phase 1/2 study of the GSPT1-directed MGD ...

NEW YORK, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Skye Bioscience, Inc. ("Skye Bioscience, Inc." or the "Company") (NASDAQ: SKYE) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Skye Bioscience, Inc. investors who were adversely affected by alleged securities fraud between November 4, 2024 and October 3, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/p ...

SAN DIEGO--(BUSINESS WIRE)---- $TLX #Telix--Robbins LLP: Company: Telix Pharmaceuticals Ltd. (NASDAQ: TLX) is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. What is the class period? February 21, 2025 - August 28, 2025 What is the case about? Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or acquired Telix securities during the class p ...

We recently published 7 Best ASX Stocks to Buy Right Now.  Immutep Limited (NASDAQ:IMMP) is one of the best ASX stocks. Immutep Limited (NASDAQ:IMMP) is a biotechnology company developing therapies for cancer and autoimmune diseases. The firm’s shares underwent notable traction earlier this week after Indian firm Dr. Reddy’s Laboratories Ltd.’s subsidiary entered into an agreement with its subsidiary to develop and commercialize a drug outside countries in North America, Europe, Japan, and Greater China. ...

We recently published 7 Best ASX Stocks to Buy Right Now.  Mesoblast Limited (NASDAQ:MESO) is one of the best ASX stocks. Mesoblast Limited (NASDAQ:MESO) is a biotechnology company developing treatments for inflammatory diseases, heart failure, and other ailments. On November 25th, Jefferies upgraded the firm’s shares to Buy from Hold and increased the share price target to AUD3.30 from AUD3.00. The financial firm cited Mesoblast Limited (NASDAQ:MESO)’s Ryoncil drug as the reason behind its optimism. Jeff ...

Key Takeaways RCUS fell 14.4% after discontinuing the phase III STAR-221 study in upper GI cancers following OS data.The domvanalimab combo failed to beat nivolumab plus chemo on survival, though safety was comparable.RCUS will pivot focus to casdatifan and other oncology and I&I programs, with cash funding into 2028.Shares of Arcus Biosciences, Inc. (RCUS) , a clinical-stage biopharmaceutical company, declined 14.4% following the announcement that its late-stage STAR-221 study was discontinued for futility ...

Los Angeles, CA, Dec. 15, 2025 (GLOBE NEWSWIRE) -- The Lundquist Institute (TLI) and its start-up company Vitalex Biosciences (Vitalex) are pleased to announce that the second-generation fungal vaccine candidate known as VXV‑01, which was developed using a proprietary TLI vaccine technology platform, is poised to move forward in development up to and including Phase 1 clinical evaluation — enabled by a major contract awarded to a collaboration  consortium of Vitalex and Appili Therapeutics (TSX: APLI; OTCPi ...

Three storm-lit steel safes sit in the rain with glowing stacks of cash at their base. Key Points Capital returns in the form of share buybacks and dividend payments are an attractive element for many investors, helping to boost value in ways other than through share price growth. In the current environment, companies able to provide solid cash flow for these returns are increasingly rare. Three names to keep an eye on for their cash flow and returns include Gilead Sciences, Applied Materials, and Qual ...